U.S. commercial launch strategy for an FDA-cleared wound-care product.

A foreign biotech manufacturer had secured FDA clearance for a topically applied wound-care product indicated across a broad range of acute and chronic wounds but had no U.S. commercial presence.

The company needed more than a marketing plan — it needed a path to revenue that accounted for a hard reality of the wound-care market: most wound care in the U.S. is paid by Medicare, and a brand-new product faces a multi-quarter wait for coverage and coding before reimbursement-dependent channels open. The question was how to build commercial momentum before reimbursement matured, without overstating what an FDA device clearance does and does not allow a company to claim.

Wellguidant Advisors built an end-to-end commercialization strategy sequenced around reimbursement reality rather than against it.

• Market and opportunity sizing: Mapped the addressable opportunity across the major chronic-wound categories — diabetic foot ulcers, venous leg ulcers, and pressure ulcers — and identified where each is treated across care settings, so commercial prioritization could follow the patients.
• Payer and reimbursement pathway analysis: Modeled the payer mix for each wound type and the distinct reimbursement mechanics of each care setting, then used that to sequence channel entry — leading with settings where the company had high control over near-term revenue and treating the longer Medicare coverage and payment pathway as a parallel, longer-horizon workstream.
• Customer segmentation: Defined three priority segments — skilled nursing facilities, hospitals, and cash-pay provider practices — each with its own buying dynamics, and built targeted account profiles, decision-maker maps, and prioritization filters for each.
• Go-to-market execution toolkit: For every segment, developed stakeholder-specific value propositions, field-ready talk tracks, objection-and-response guides, and a structured outreach cadence, alongside KPI benchmarks to measure and tune the funnel after launch.
• KOL and channel development: Identified key opinion leaders and reference accounts to anchor early adoption and word-of-mouth, and outlined a regional targeting approach concentrating effort in high-prevalence geographies.
• Compliance discipline: Throughout, held messaging to the boundaries of the product's FDA device clearance — anchoring efficacy claims to published evidence and routing copy through regulatory review before activation.

The client received a phased launch playbook that turned a reimbursement constraint into a sequencing strategy: fast early wins in self-pay and facility channels, volume building in skilled nursing, and the slower hospital and Medicare pathways started early so they would mature on schedule. Each segment came with the targeting logic, messaging, and metrics needed to execute immediately.

For a manufacturer entering the U.S. from abroad, the most expensive mistakes are launching into the wrong channel first and assuming reimbursement will arrive on the company's timeline. By grounding the commercial strategy in payer reality and care-setting economics, we gave the client a route to revenue that didn't depend on coverage decisions outside its control.